Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers.
Camille V TrinidadAshley L TetlowLeonidas E BantisAndrew K GodwinPublished in: Cancer prevention research (Philadelphia, Pa.) (2021)
More than two-thirds of all women diagnosed with epithelial ovarian cancer (EOC) will die from the disease (>14,000 deaths annually), a fact that has not changed considerably in the last three decades. Although the 5-year survival rates for most other solid tumors have improved steadily, ovarian cancer remains an exception, making it the deadliest of all gynecologic cancers and five times deadlier than breast cancer. When diagnosed early, treatment is more effective, with a 5-year survival rate of up to 90%. Unfortunately, most cases are not detected until after the cancer has spread, resulting in a dismal 5-year survival rate of less than 30%. Current screening methods for ovarian cancer typically use a combination of a pelvic examination, transvaginal ultrasonography, and serum cancer antigen 125 (CA125), but these have made minimal impact on improving mortality. Thus, there is a compelling unmet need to develop new molecular tools that can be used to diagnose early-stage EOC and/or assist in the clinical management of the disease after a diagnosis, given that more than 220,000 women are living with ovarian cancer in the United States and are at risk of recurrence. Here, we discuss the state of advancing liquid-based approaches for improving the early detection of ovarian cancer.See all articles in this Special Collection Honoring Paul F. Engstrom, MD, Champion of Cancer Prevention.
Keyphrases
- papillary thyroid
- early stage
- squamous cell
- free survival
- polycystic ovary syndrome
- childhood cancer
- magnetic resonance imaging
- cardiovascular events
- squamous cell carcinoma
- pregnancy outcomes
- young adults
- rectal cancer
- type diabetes
- lymph node
- breast cancer risk
- metabolic syndrome
- cardiovascular disease
- skeletal muscle
- combination therapy
- replacement therapy